Clostridium difficile colitis (CDC) is an infection of the intestine caused by the bacteria Clostridioides difficile. Symptoms may be mild, but life-threatening complications can develop. Those at ...
Discover Merck's groundbreaking patent on genetic markers linked to enhanced C. difficile treatment responses. Learn how personalized therapy can improve patient outcomes.
EXL-01 is under clinical development by Exeliom Biosciences and currently in Phase II for Clostridioides difficile Infections (Clostridium difficile Associated Disease). According to GlobalData, Phase ...
The findings show a complex intercontinental transport route for microbes like E. coli, Staphylococcus saprophyticus, and Clostridium difficile, protected from ultraviolet light and dehydration by ...
New analyses extend data on beneficial effects of ibezapolstat on the gut microbiomeConfirmed ibezapolstat's favorable pharmacokinetics showing low systemic exposure and high colonic ...